Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05773040 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
A Phase 1 study of Lymphomas and B-cell Lymphomas, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT05773040: Recruiting Phase 1 study of Lymphomas and B-cell Lymphomas, sponsored by M.D. Anderson Cancer Center.
NCT05773040 is a Phase 1 study of Lymphomas and B-cell Lymphomas that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 33 participants, below the 1,090-participant average among 7 other Lymphomas trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05773040, a Phase 1 study of Lymphomas and B-cell Lymphomas, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.
Conditions Studied
Interventions
- PROCEDURE Leukapheresis
- DRUG JV-213
Study Locations (1)
Texas
- The University of Texas M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-04-14 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT05773040 shows while recruiting
NCT05773040 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,090-participant average among 7 other Lymphomas trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Lymphomas appearing as the primary indexed condition, and to 2 interventions - of which Leukapheresis is the first listed.
NCT05773040 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05773040 about?
NCT05773040 is a clinical study titled "A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas". To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.
What is the current status of trial NCT05773040?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2023-04-14. Estimated completion is 2027-12-31.
What conditions does trial NCT05773040 study?
This clinical trial studies the following conditions: Lymphomas, B-cell Lymphomas.
What interventions are being tested in trial NCT05773040?
The interventions under investigation include: Leukapheresis (PROCEDURE), JV-213 (DRUG).
Who is sponsoring clinical trial NCT05773040?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05773040 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphomas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas
COMPLETED · Phase 1
-
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
COMPLETED · Phase 1
-
Assess the Oral Bioavailability of New ABT-263 Formulations
COMPLETED · Phase 1
-
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
COMPLETED · Phase 1
-
Collection of Tissue Samples for Cancer Research
RECRUITING
-
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI